Zevra Therapeutics (ZVRA) Convertible Debt (2014 - 2020)

Zevra Therapeutics (ZVRA) has 7 years of Convertible Debt data on file, last reported at $67.7 million in Q4 2020.

• Quarterly Convertible Debt fell 12.52% year-over-year to $67.7 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $67.7 million (down 12.52% YoY) and the FY2020 annual result came in at $67.7 million, down 12.52% from the prior year.
• Convertible Debt retreated to $67.7 million in Q4 2020, from $77.3 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $92.3 million in Q3 2017 to a low of $67.7 million in Q4 2020.
• A 5-year average of $84.5 million and a median of $89.4 million in 2017 frame the typical range for Convertible Debt.
• Annual changes were most pronounced in 2016 — Convertible Debt soared 1130.03% — and 2019, when it decreased 19.06%.
• Tracing ZVRA's Convertible Debt over 5 years: stood at $91.2 million in 2016, then fell by 1.94% to $89.4 million in 2017, then decreased by 12.63% to $78.1 million in 2018, then slipped by 0.98% to $77.3 million in 2019, then fell by 12.52% to $67.7 million in 2020.
• The last three Convertible Debt figures came in at $67.7 million (Q4 2020), $77.3 million (Q4 2019), and $70.6 million (Q3 2019), per Business Quant data.